Asston Pharmaceuticals Ltd
Incorporated in 2019, Asston Pharmaceuticals Ltd is in the business of manufacturing pharmaceutical products.[1]
- Market Cap ₹ 69.8 Cr.
- Current Price ₹ 82.0
- High / Low ₹ 126 / 61.0
- Stock P/E 18.0
- Book Value ₹ 45.6
- Dividend Yield 0.00 %
- ROCE 16.8 %
- ROE 15.5 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Earnings include an other income of Rs.6.12 Cr.
- Company has high debtors of 524 days.
- Working capital days have increased from 259 days to 434 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE SME IPO
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 9.60 | 6.54 | 16.03 | 25.04 | 25.47 | |
| 9.96 | 5.02 | 12.21 | 19.60 | 26.04 | |
| Operating Profit | -0.36 | 1.52 | 3.82 | 5.44 | -0.57 |
| OPM % | -3.75% | 23.24% | 23.83% | 21.73% | -2.24% |
| 0.96 | 0.65 | 0.25 | 0.57 | 6.12 | |
| Interest | 0.43 | 0.72 | 0.76 | 0.95 | 0.63 |
| Depreciation | 0.01 | 0.04 | 0.06 | 0.04 | 0.32 |
| Profit before tax | 0.16 | 1.41 | 3.25 | 5.02 | 4.60 |
| Tax % | 31.25% | 25.53% | 25.23% | 23.11% | 15.87% |
| 0.11 | 1.06 | 2.43 | 3.85 | 3.87 | |
| EPS in Rs | 1.57 | 15.14 | 31.00 | 6.14 | 4.55 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 57% |
| TTM: | 2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 54% |
| TTM: | 2% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 28% |
| 3 Years: | 26% |
| Last Year: | 16% |
Balance Sheet
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 0.70 | 0.70 | 0.78 | 6.27 | 8.51 |
| Reserves | 0.23 | 1.29 | 6.40 | 4.76 | 30.35 |
| 3.31 | 5.24 | 6.82 | 7.25 | 5.11 | |
| 5.25 | 6.46 | 6.70 | 9.84 | 7.68 | |
| Total Liabilities | 9.49 | 13.69 | 20.70 | 28.12 | 51.65 |
| 0.92 | 1.13 | 0.97 | 0.96 | 10.69 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 8.57 | 12.56 | 19.73 | 27.16 | 40.96 | |
| Total Assets | 9.49 | 13.69 | 20.70 | 28.12 | 51.65 |
Cash Flows
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| -1.19 | -0.32 | -3.97 | -0.03 | -10.18 | |
| 0.00 | -0.91 | -0.01 | 0.73 | -9.91 | |
| 1.29 | 1.21 | 3.86 | -0.51 | 21.18 | |
| Net Cash Flow | 0.10 | -0.01 | -0.12 | 0.19 | 1.09 |
| Free Cash Flow | -1.19 | -0.57 | -3.98 | -0.06 | -20.24 |
| CFO/OP | 322% | -20% | -92% | -0% | 1,368% |
Ratios
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 243.33 | 480.53 | 380.71 | 357.86 | 524.07 |
| Inventory Days | 27.24 | 204.29 | 53.91 | 18.59 | 16.14 |
| Days Payable | 246.78 | 754.51 | 217.50 | 154.11 | 120.76 |
| Cash Conversion Cycle | 23.79 | -69.70 | 217.12 | 222.34 | 419.45 |
| Working Capital Days | -12.17 | 43.53 | 162.80 | 178.86 | 434.22 |
| ROCE % | 37.14% | 37.78% | 36.62% | 16.80% |
Insights
In beta| Dec 2019 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Total Production Volume MT |
|
||||||
| Inventory Holding Days Days |
|||||||
| Export Presence (Number of Countries) Number |
|||||||
| Installed Tablet Production Capacity (Unit I) Crore Tablets/Month |
|||||||
| Number of Employees Number |
|||||||
| Capacity Utilization (Tablets) % |
|||||||
| Order Book USD |
|||||||
| Proposed Total Tablet Production Capacity (Unit I + Unit II) Crore Tablets/Month |
|||||||
| Registered Trademarks Number |
|||||||
Extracted by Screener AI
Documents
Announcements
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On 29Th May 2026
29 May - Board approved audited FY26 and half-year results on 29 May 2026; auditors issued unmodified opinion.
-
Audited Financial Results For The Financial Year Ended 31St March, 2026.
29 May - Board approved audited FY and half-year results ended 31 March 2026; auditors issued unmodified opinion.
-
Audited Financial Results For The Financial Year Ended 31St March, 2026.
29 May - Board approved audited FY26 and H1 FY26 results; auditors issued unmodified opinion.
-
Board Meeting Intimation for Approving Audited Financial Ressults
21 May - Board meets on 29 May 2026 to approve audited FY26 and Q4 results and deviation statement.
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30 Apr - Asston Pharmaceuticals confirms it is not a large corporate; outstanding borrowing was Rs 5.04 crore as of 31 Mar 2024.
Business Overview:[1]
APL offers pharmaceutical products in the form of Tablet, Capsules, Syrup, Sachet and Injection (LVP and SVP). The company has WHO GMP approved manufacturing units for manufacturing
the entire products range and also has
a tie up with a NABL Accredited Laboratory.